Drugs / Ulixertinib
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05804227 | Apr 2023 → Sep 2027 expected | glioma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT05985954 | Jan 2024 → Mar 2028 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04145297 | Mar 2020 → Jun 2022 | digestive system neoplasm | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT03454035 | Jan 2018 → Jul 2026 overdue | malignant pancreatic neoplasm, melanoma | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06773195 | Jan 2025 → Jan 2028 expected | myelofibrosis | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06411821 | May 2024 → May 2027 expected | histiocytic and dendritic cell neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05221320 | May 2022 → May 2024 | digestive system cancer, soft tissue neoplasm | BioMed Valley Discoveries, Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04488003 | Jan 2021 → Feb 2023 | neoplasm | BioMed Valley Discoveries, Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06400225 | Jul 2019 → Dec 2026 expected | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03698994 | Nov 2018 → Mar 2022 overdue | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, bone osteosarcoma +12 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03155620 | Jul 2017 → Mar 2025 overdue | Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, conventional osteosarcoma +13 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2027 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04566393 | — | cholangiocarcinoma, colorectal cancer, esophageal cancer, gastric cancer +10 | xCures | Available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulixertinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06773195 ↗ |
| Known as | BVD-523 | “Ulixertinib (BVD-523) is an oral, first-in-class ERK1/2 inhibitor” NCT04566393 ↗1“Ulixertinib (BVD-523)” NCT06411821 ↗ |
| Action | Inhibit | “ERK inhibitor ulixertinib” NCT03454035 ↗ |
| Modality | Small molecule | “small molecule ERK 1/2 inhibitor” NCT05221320 ↗ |
| Route | Oral | “receive ulixertinib (BVD-523FB) PO BID” NCT02465060 ↗ |